Phathom Pharmaceuticals (PHAT) to Release Quarterly Earnings on Thursday

Phathom Pharmaceuticals (NASDAQ:PHAT) is set to announce its earnings results before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of ($1.13) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Phathom Pharmaceuticals (NASDAQ:PHAT) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.12. The business had revenue of $0.68 million during the quarter, compared to analysts’ expectations of $0.93 million. During the same period last year, the company earned ($1.33) earnings per share. On average, analysts expect Phathom Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Phathom Pharmaceuticals Price Performance

PHAT stock opened at $10.24 on Wednesday. The firm’s fifty day simple moving average is $9.80 and its 200-day simple moving average is $8.70. Phathom Pharmaceuticals has a 12 month low of $6.07 and a 12 month high of $17.02. The company has a market capitalization of $599.24 million, a P/E ratio of -2.64 and a beta of 0.67.

Analysts Set New Price Targets

Several research firms recently issued reports on PHAT. Stifel Nicolaus began coverage on shares of Phathom Pharmaceuticals in a research note on Friday, May 3rd. They issued a “buy” rating and a $24.00 target price for the company. Needham & Company LLC reiterated a “buy” rating and issued a $26.00 target price on shares of Phathom Pharmaceuticals in a research note on Friday, May 3rd. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $22.00.

Insiders Place Their Bets

In other Phathom Pharmaceuticals news, insider Terrie Curran sold 16,851 shares of the company’s stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $9.11, for a total transaction of $153,512.61. Following the completion of the transaction, the insider now directly owns 410,784 shares in the company, valued at $3,742,242.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Phathom Pharmaceuticals news, insider Terrie Curran sold 16,851 shares of the company’s stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $9.11, for a total transaction of $153,512.61. Following the completion of the transaction, the insider now directly owns 410,784 shares in the company, valued at $3,742,242.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Molly Henderson sold 3,435 shares of the company’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $11.10, for a total transaction of $38,128.50. Following the transaction, the chief financial officer now owns 95,263 shares of the company’s stock, valued at $1,057,419.30. The disclosure for this sale can be found here. 24.10% of the stock is currently owned by company insiders.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.